Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 2
2004 4
2005 2
2006 1
2008 3
2009 6
2010 4
2011 5
2012 7
2013 4
2014 3
2015 7
2016 7
2017 10
2018 14
2019 27
2020 20
2021 9
2022 12
2023 14
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

154 results

Results by year

Filters applied: . Clear all
Page 1
RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma.
Nowakowski GS, Yoon DH, Mondello P, Joffe E, Peters A, Fleury I, Greil R, Ku M, Marks R, Kim K, Zinzani PL, Trotman J, Sabatelli L, Waltl EE, Winderlich M, Sporchia A, Kurukulasuriya NC, Cordoba R, Hess G, Salles G. Nowakowski GS, et al. Among authors: kim k. Ann Hematol. 2023 Jul;102(7):1773-1787. doi: 10.1007/s00277-023-05196-4. Epub 2023 May 12. Ann Hematol. 2023. PMID: 37171597 Free PMC article.
Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study.
Nowakowski GS, Yoon DH, Peters A, Mondello P, Joffe E, Fleury I, Greil R, Ku M, Marks R, Kim K, Zinzani PL, Trotman J, Huang D, Waltl EE, Winderlich M, Kurukulasuriya NC, Ambarkhane S, Hess G, Salles G. Nowakowski GS, et al. Among authors: kim k. Clin Cancer Res. 2022 Sep 15;28(18):4003-4017. doi: 10.1158/1078-0432.CCR-21-3648. Clin Cancer Res. 2022. PMID: 35674661 Free PMC article.
Letter--The Authors Respond.
Kim K, DiDomenico RJ, Touchette DR, Walton SM. Kim K, et al. J Manag Care Spec Pharm. 2017 May;23(5):599-600. doi: 10.18553/jmcp.2017.23.5.599. J Manag Care Spec Pharm. 2017. PMID: 28448774 Free PMC article.
Recent Progress in Solid-State Nanopores.
Lee K, Park KB, Kim HJ, Yu JS, Chae H, Kim HM, Kim KB. Lee K, et al. Adv Mater. 2018 Oct;30(42):e1704680. doi: 10.1002/adma.201704680. Epub 2018 Sep 10. Adv Mater. 2018. PMID: 30260506 Review.
Glucose-dependent control of leucine metabolism by leucyl-tRNA synthetase 1.
Yoon I, Nam M, Kim HK, Moon HS, Kim S, Jang J, Song JA, Jeong SJ, Kim SB, Cho S, Kim Y, Lee J, Yang WS, Yoo HC, Kim K, Kim MS, Yang A, Cho K, Park HS, Hwang GS, Hwang KY, Han JM, Kim JH, Kim S. Yoon I, et al. Among authors: kim k. Science. 2020 Jan 10;367(6474):205-210. doi: 10.1126/science.aau2753. Epub 2019 Nov 28. Science. 2020. PMID: 31780625
Alpha-Hederin Nanopore for Single Nucleotide Discrimination.
Jeong KB, Luo K, Lee H, Lim MC, Yu J, Choi SJ, Kim KB, Jeon TJ, Kim YR. Jeong KB, et al. ACS Nano. 2019 Feb 26;13(2):1719-1727. doi: 10.1021/acsnano.8b07797. Epub 2019 Jan 23. ACS Nano. 2019. PMID: 30657663
154 results